Navigation Links
Cephalon Reports Record Earnings and Raises 2010 Guidance
Date:10/28/2010

2010, to exclude proceeds related to the settlement of litigation in Europe ($2.1M), offset by charges related to the acquisition of Mepha ($0.2M). In 2009, to exclude charges related to the acquisition of Arana Therapeutics Limited ($0.6M).  (4) To exclude the change in fair value of the Ception contingent consideration.(5) To exclude costs related to restructurings.(6) To exclude charges incurred in exchange for license rights to certain of XOMA Ltd.’s proprietary antibody library materials.(7) To exclude imputed interest expense associated with convertible debt ($15.1M in 2010; $17.0M in 2009).(8) In 2009, to exclude $0.4M gain on foreign exchange of Australian Dollar acquisition funds.  (9) To reflect the tax effect of pre-tax adjustments at applicable tax rates and certain other tax adjustments primarily related to changes in valuation allowances and other changes in tax assets and liabilities.CEPHALON, INC. AND SUBSIDIARIESReconciliation of GAAP Net Income to Adjusted Net Income Attributable to Cephalon, Inc.(Unaudited)Nine Months EndedSeptember 30,20102009GAAP NET INCOME ATTRIBUTABLE TO CEPHALON, INC.

$
332,129 $
246,069 Cost of sales adjustments24,225

(1)78,146

(1)Research and development adjustments2,690

(2)4,404

(2)Selling, general and administrative adjustments9,581

(3)4,379

(3)Change in fair value of contingent consideration adjustment,314

(4)- Restructuring charges7,638

(5)3,944

(5)In-process research and development adjustments- 46,118

(6)Interest expense adjustment50,072

(7)40,459

(7)Other (income) expense adjustment,567

(8)(40,011)

(8)Arana noncontrolling interest adjustments- (819)

(9)Income tax adjustment(64,293)

(10)(54,192)

(10)*Noncontrolling Interest adjustments:Other revenues(31)30 Research and development ,377 25,519 Selling, general and administrative3,462 7,373 Interest income(7)
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
2. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
3. Cephalon Completes Acquisition of Arana Therapeutics
4. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
7. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
8. Cephalons New Product Launches Pace Record 2008 Sales
9. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
10. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
11. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Md. (PRWEB) October 21, 2014 Shimadzu ... an LC/MS/MS data tool for the pain management and ... of data processing and review by allowing users to ... to clinicians. , QuantAnalytics allows analysts to filter ... This expedites data processing by eliminating the need to ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... Research and Markets  has announced the addition of ... Geography - Global Analysis and Forecast (2014 - 2020)" ... electronics, also called as polymer electronics or plastic electronics, ... small conductive molecules and electrically conductive polymers. It is ... carbon based, made using synthetic strategies developed in the ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... 7 /PRNewswire-FirstCall/ - Oncothyreon Inc. (the,"Company") (Nasdaq: ... development of innovative therapeutic products for the treatment ... its fourth quarter and,full year 2007 financial results ... the U.S. and Canadian markets. Following the release, ...
... Corporation,(Nasdaq: ACEL ) today reported its financial results ... recorded a net loss of approximately $1.7 million, or ... fiscal quarter ended,Jan. 31, compared to a net loss ... share, for the second quarter of fiscal 2007. The ...
... PARK, Ill., March 7 Abbott (NYSE: ... Annual Global Healthcare,Conference on Tuesday, March 18, 2008. ... financial officer, will make a formal,presentation on the ... live audio webcast of the presentation will be ...
Cached Biology Technology:Alfacell Reports Financial Results for Second Quarter of Fiscal 2008 2Alfacell Reports Financial Results for Second Quarter of Fiscal 2008 3Alfacell Reports Financial Results for Second Quarter of Fiscal 2008 4Alfacell Reports Financial Results for Second Quarter of Fiscal 2008 5
(Date:10/15/2014)... spreading rapidly and to an unexpected extent. The outbreak ... and the virus shows a new disease dynamic in ... this reason, the German National Academy of Sciences Leopoldina, ... and the Union of the German Academies of Sciences ... epidemic today. , In the statement the academies call ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... growing mobile commerce market releases photos and video of the recent ... October 13 th . Gino Pereira , ... angel investor Mr. Chad A. Verdi rang the bell.  ... his investors and employees "for their work and dedication in bringing ...
(Date:10/15/2014)... 15, 2014   Neurotechnology , a provider ... availability of the VeriLook Surveillance 3.0 software ... real-time biometric face identification using live video streams ... The new version not only identifies faces in ... objects while they are moving through the video ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... Dartmouth researchers use individual genetic data to reveal the powers ... influences human health and what genes can reveal about the ... in the Sept. 11 issue of the American Journal ... Professor Scott Williams analyzed how personal genetic testing companies are ...
... turning waste biomass such as dead trees, agricultural ... to power conventional engines has been licensed by the ... LLC, a private biofuels company based in Sacramento, Calif. ... industry: the ultra-low-sulfur biofuel does not require additional refinement ...
... is one of the most common neuropsychiatric disorders ... with the disorder. Key symptoms of ADHD include ... ability to focus attention. Clinically, three different ADHD ... primarily hyperactive/impulsive subtype, and a combined subtype in ...
Cached Biology News:Dartmouth researchers get personal with genetics 2Dartmouth researchers get personal with genetics 3UGA licenses technology to make fuel from dead forests and agricultural waste 2The role of genetic factors in adult ADHD 2The role of genetic factors in adult ADHD 3The role of genetic factors in adult ADHD 4The role of genetic factors in adult ADHD 5The role of genetic factors in adult ADHD 6
Liquid. PBS containing 10 mM NaN 3 . AVOID FREEZE/THAW CYCLES. Recognizes α1, 2, 3, 5, 6 and 7 subunits of 20S proteasome. ...
Mouse monoclonal antibody to Lats2....
... Membrane Protein 2, Synaptobrevin 2). ... homology with any other known ... expected that the antibody will ... multata and bovine due to ...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
Biology Products: